Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ADMA
stocks logo

ADMA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
139.83M
+18.96%
0.187
-59.42%
145.00M
+26.3%
0.197
+78.79%
154.10M
+26.33%
0.220
+57.14%
Estimates Revision
The market is revising Upward the revenue expectations for ADMA Biologics, Inc. (ADMA) for FY2025, with the revenue forecasts being adjusted by 0.91% over the past three months. During the same period, the stock price has changed by 19.21%.
Revenue Estimates for FY2025
Revise Upward
up Image
+0.91%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+3.84%
In Past 3 Month
Stock Price
Go Up
up Image
+19.21%
In Past 3 Month
Wall Street analysts forecast ADMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADMA is 32.00 USD with a low forecast of 32.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ADMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADMA is 32.00 USD with a low forecast of 32.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 20.110
sliders
Low
32.00
Averages
32.00
High
32.00
Current: 20.110
sliders
Low
32.00
Averages
32.00
High
32.00
Raymond James
Strong Buy
maintain
$25 -> $32
2025-05-08
Reason
Raymond James
Price Target
$25 -> $32
2025-05-08
maintain
Strong Buy
Reason
Cantor Fitzgerald
Kristen Kluska
Buy
Reiterates
$25
2025-03-04
Reason
Cantor Fitzgerald
Kristen Kluska
Price Target
$25
2025-03-04
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for ADMA Biologics Inc (ADMA.O) is 23.94, compared to its 5-year average forward P/E of 0.41. For a more detailed relative valuation and DCF analysis to assess ADMA Biologics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.41
Current PE
23.94
Overvalued PE
52.28
Undervalued PE
-51.46

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
10.23
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
19.69
Undervalued EV/EBITDA
0.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
4.45
Current PS
0.00
Overvalued PS
7.05
Undervalued PS
1.85
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 719.51% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ADMA News & Events

Events Timeline

(ET)
2025-11-05
16:52:55
Adma Biologics increases FY26 revenue forecast to a minimum of $630M, up from at least $625M.
select
2025-11-05
16:51:35
Adma Biologics increases FY25 revenue forecast to a minimum of $510M, up from at least $500M.
select
2025-11-05
16:50:05
Adma Biologics announces Q3 earnings per share of 15 cents, below consensus estimate of 16 cents.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
6.5
11-27NASDAQ.COM
Wall Street Analysts Predict a 60.24% Surge for Adma Biologics (ADMA): Important Insights Before You Invest

  • Stock Performance: Adma Biologics (ADMA) shares have risen 23.3% recently, closing at $19.14, with Wall Street analysts projecting a mean price target of $30.67, suggesting a potential upside of 60.2%.

  • Analyst Price Targets: While the consensus price target shows strong agreement among analysts, there are concerns about the reliability of these targets, as they may be influenced by business relationships and could mislead investors.

  • Earnings Estimates: Analysts have revised ADMA's earnings estimates upward, indicating optimism about the company's performance, which historically correlates with positive stock price movements.

  • Investment Caution: Investors are advised to approach price targets with skepticism and consider them as one of many factors in their investment decisions, rather than relying solely on them for potential returns.

[object Object]
Preview
4.0
11-26NASDAQ.COM
Adma Biologics (ADMA) Receives Upgrade to Buy: Key Information You Need to Know

  • Zacks Rank Upgrade: Adma Biologics has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, indicating a positive outlook for the company's stock price.

  • Earnings Estimate Revisions: The Zacks rating system emphasizes the importance of earnings estimate revisions, which have shown a strong correlation with near-term stock movements, making it a valuable tool for investors.

  • Analyst Consensus: Over the past three months, the Zacks Consensus Estimate for Adma Biologics has increased by 1.6%, reflecting analysts' growing confidence in the company's earnings potential.

  • Market Positioning: The upgrade places Adma Biologics in the top 20% of Zacks-covered stocks, suggesting it is well-positioned for potential market-beating returns in the near term.

[object Object]
Preview
2.0
11-25NASDAQ.COM
ADMA Surpasses Important Moving Average Threshold
  • 52 Week Range: ADMA's stock has a 52-week low of $13.50 and a high of $25.67, with the last trade recorded at $18.32.
  • Market Analysis: The article references other stocks that have recently crossed above their 200-day moving average.
  • Author's Perspective: The views expressed in the article are solely those of the author and do not necessarily represent Nasdaq, Inc.
  • Stock Performance Insight: The information highlights the current performance and volatility of ADMA's stock within the specified time frame.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is ADMA Biologics Inc (ADMA) stock price today?

The current price of ADMA is 20.11 USD — it has increased 1.98 % in the last trading day.

arrow icon

What is ADMA Biologics Inc (ADMA)'s business?

ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.

arrow icon

What is the price predicton of ADMA Stock?

Wall Street analysts forecast ADMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADMA is 32.00 USD with a low forecast of 32.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is ADMA Biologics Inc (ADMA)'s revenue for the last quarter?

ADMA Biologics Inc revenue for the last quarter amounts to 134.22M USD, increased 12.00 % YoY.

arrow icon

What is ADMA Biologics Inc (ADMA)'s earnings per share (EPS) for the last quarter?

ADMA Biologics Inc. EPS for the last quarter amounts to 0.15 USD, decreased 0.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for ADMA Biologics Inc (ADMA)'s fundamentals?

The market is revising Upward the revenue expectations for ADMA Biologics, Inc. (ADMA) for FY2025, with the revenue forecasts being adjusted by 0.91% over the past three months. During the same period, the stock price has changed by 19.21%.
arrow icon

How many employees does ADMA Biologics Inc (ADMA). have?

ADMA Biologics Inc (ADMA) has 677 emplpoyees as of December 05 2025.

arrow icon

What is ADMA Biologics Inc (ADMA) market cap?

Today ADMA has the market capitalization of 4.79B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free